Avraham Gabay Sells 73,360 Shares of Oramed Pharmaceuticals (NASDAQ:ORMP) Stock

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) CFO Avraham Gabay sold 73,360 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $4.51, for a total transaction of $330,853.60. Following the transaction, the chief financial officer directly owned 671,785 shares of the company’s stock, valued at approximately $3,029,750.35. This represents a 9.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Oramed Pharmaceuticals Stock Performance

Oramed Pharmaceuticals stock traded down $0.01 during midday trading on Thursday, reaching $4.60. 360,793 shares of the stock were exchanged, compared to its average volume of 241,456. The company’s fifty day moving average is $4.08 and its 200-day moving average is $3.62. The firm has a market cap of $188.26 million, a PE ratio of 1.78 and a beta of 1.21. Oramed Pharmaceuticals Inc. has a 52 week low of $1.98 and a 52 week high of $5.19.

Institutional Trading of Oramed Pharmaceuticals

A number of large investors have recently modified their holdings of the business. Bank of America Corp DE grew its holdings in shares of Oramed Pharmaceuticals by 2.7% during the first quarter. Bank of America Corp DE now owns 146,152 shares of the biotechnology company’s stock worth $497,000 after purchasing an additional 3,909 shares in the last quarter. OMERS ADMINISTRATION Corp purchased a new stake in Oramed Pharmaceuticals in the first quarter valued at approximately $63,000. Dimensional Fund Advisors LP lifted its position in Oramed Pharmaceuticals by 5.1% during the first quarter. Dimensional Fund Advisors LP now owns 158,209 shares of the biotechnology company’s stock valued at $538,000 after purchasing an additional 7,738 shares during the last quarter. Hillsdale Investment Management Inc. bought a new stake in Oramed Pharmaceuticals during the first quarter valued at approximately $331,000. Finally, Kathmere Capital Management LLC purchased a new position in Oramed Pharmaceuticals in the 1st quarter worth approximately $51,000. Institutional investors own 12.73% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Oramed Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, June 11th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat, Oramed Pharmaceuticals has an average rating of “Hold”.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.